Targets › AOC3
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Sep 2027.
Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia. Has a preference for the primary monoamines methylamine and benzylamine. (UniProt, Q16853)
Open in Phaseline: the race on AOC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eccogene | ECC0509 Semicarbazide sensitive amine oxidase (SSAO) inhibitor | AOC3 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis | Sep 2027 |
Metabolic Dysfunction-associated Steatohepatitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.